XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Infectious Diseases Channel
subscribe to Infectious Diseases newsletter

Latest Research : Infectious Diseases

   DISCUSS   |   EMAIL   |   PRINT
Vaccine can prevent against antibiotic-resistant strain of anthrax
Dec 16, 2004, 16:31, Reviewed by: Dr.



 
Rapidly distributing antibiotics to people exposed to anthrax spores during a bioterrorist attack, could by itself, prevent about 70 percent of anthrax infections, according to researchers from the Johns Hopkins Bloomberg School of Public Health. To increase the prevention rate to 90 percent, their study found that at least 63 percent of the population would need to be immunized with vaccine before an anthrax attack, which might not be practical. However, the study found that anthrax vaccination given even after an attack could be beneficial in reducing the length of time antibiotic treatment would be needed. These findings could be an important tool for policymakers who must develop effective strategies for containing an anthrax outbreak. The study is published in the December 16, 2004, edition of Nature.

The Hopkins researchers developed a probability model to predict how many cases of anthrax could be prevented under varying conditions. The study found that about 70 percent of anthrax cases could be prevented if antibiotics were distributed within 6 days after exposure and patients were to take them for 60 days. Prevention rates dropped below 50 percent if antibiotics were delayed more than 10 days. In 2001, some postal workers did not begin taking antibiotics until 9 days after exposure.

The current licensed anthrax vaccine requires six doses over an 18-month period to provide immunity. The researchers looked at what impact a new and improved anthrax vaccine could have, and evaluated a range of vaccine characteristics, which could begin to provide immunity ranging between 7 and 28 days. When vaccine was distributed along with antibiotics after an attack, the researchers calculated that vaccine prevented few additional cases from occurring when compared to just rapid use of antibiotics. However, they found that if the vaccine is 95 percent effective, it could reduce the time that antibiotics would be needed up to 43 days.

An 80 percent effective vaccine could reduce time on antibiotics by up to 23 days. The vaccine could also prevent cases if an antibiotic-resistant strain of anthrax were used in an attack.

"Our study highlights the need for rapid distribution of antibiotics to minimize casualties from an anthrax outbreak," explained Ron Brookmeyer, PhD, lead author of the study and professor in the Department of Biostatistics at the Bloomberg School of Public Health. "But a long course of antibiotics is not ideal, and a new improved anthrax vaccine could be especially helpful in reducing duration of antibiotic treatments."

###

"Public health vaccination policies for containing an anthrax outbreak" was written by Ron Brookmeyer, Elizabeth Johnson and Robert Bollinger. Brookmeyer and Johnson are with the Department of Biostatistics at the Johns Hopkins Bloomberg School of Public Health. Bollinger is with the Division of Infectious Diseases at the Johns Hopkins School of Medicine.

The research was funded by the Fogarty International Center and the National Institutes of Allergy and Infectious Diseases.
 

- December 16, 2004, edition of Nature
 

 
Subscribe to Infectious Diseases Newsletter
E-mail Address:

 



Related Infectious Diseases News

Keeping A3G in action represents a new way to attack HIV
Fighting HIV With HIV Virus Itself
Retina can provide a very reliable way of diagnosing cerebral malaria
Are influenza vaccines worth the effort?
A light daily exercise program may reduce the incidence of colds
HIV exploits competition among T-cells
Mass vaccination would not be necessary in the event of a smallpox bioterrorist attack
How Ebola and Marburg viruses cause disease
Transmission of MRSA Linked to Previous Intensive Care Unit Room Occupants
Harmless GB Virus type C (GBV-C) protects against HIV infection


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us